Oxoisoindole-5-Formamide Solid Forms for Stability and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of a new generation CK1α selective molecular glue degrader, compound of formula A, lacks research on its crystalline and amorphous forms, salts, and solvates, which can significantly affect the drug's stability, solubility, and bioavailability due to polymorphism and amorphous forms' unpredictability.
Innovation Solution
The invention provides specific crystalline and amorphous forms of the oxoisoindole-5-carboxamide compound or its pharmaceutically acceptable salts and solvates, characterized by unique XRPD, DSC, and TGA patterns, enhancing stability and solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If polymorphism phenomenon occurs in solid drugs, then different crystal forms have different physical and chemical properties, but it becomes difficult to predict and control the form and quantity of polymorphic compounds
Solution Approach 1:
The patent performs preliminary characterization of the compound's solid forms by determining XRPD patterns, DSC curves, and TGA curves before clinical development. This advance identification and classification of polymorphic forms allows the team to select the most suitable crystal form for further development, avoiding unexpected issues during later stages.
Solution Approach 2:
The patent systematically investigates how different preparation conditions (solvents, temperatures, pH values) affect the formation of different crystal forms. By understanding and controlling these parameters, the team can reproducibly obtain the desired polymorphic form with consistent properties.
2Stability of the object's composition
If different crystalline forms of the same drug are used, then solubility and stability differ significantly, but this affects the uniformity, bioavailability, efficacy and safety of the drug
Solution Approach 1:
The patent identifies and characterizes specific local structural features of the compound that influence its solid form properties. By understanding these local characteristics, the team can predict which crystal forms will exhibit desired stability and solubility profiles, allowing selective development of optimal forms.
Solution Approach 2:
The patent establishes a feedback mechanism where the solid form characteristics (XRPD, DSC, TGA) are continuously monitored and correlated with drug performance. This allows the team to adjust formulation and processing conditions to maintain consistent crystal forms, ensuring uniformity and reliability across batches.
3Quantity of substance
If amorphous form of solid compounds is used, then solubility and melting point may be improved, but the form and quantity are unpredictable and affect drug stability
Solution Approach 1:
The patent performs preliminary characterization of amorphous forms by determining their XRPD patterns (showing broad halos), DSC curves (showing glass transition), and TGA curves. This advance identification allows the team to understand the properties of amorphous forms before they are formed during processing, enabling better control.
Solution Approach 2:
The patent systematically investigates how different preparation conditions (cooling rates, solvent removal conditions, pH) affect the formation and stability of amorphous forms. By controlling these parameters, the team can reproducibly generate amorphous forms with consistent properties and predictable behavior.
Data Source
Figure 1a~1b
Figure 1c~1d
Figure 1e~1f
AI summary
The present invention relates to a crystalline form or an amorphous form of an oxoisoindole-5-formamide compound or a salt and solvate thereof. Also disclosed are a composition having the crystalline form or the amorphous form, a preparation method therefor and a use thereof. The obtained crystalline form or amorphous form has good solid stability, and has very important value for drug development, and preparation development and production.